文献速递肺外科

脓肿分枝杆菌复合群肺病的手术治疗结局

Outcomes of Surgical Treatment for Mycobacterium abscessus Complex Pulmonary Disease.
PubMed 文献 · Ann Thorac Surg · 2021-04-09

该回顾性研究纳入33例在日本单中心接受肺切除术联合围手术期多药化疗的脓肿分枝杆菌复合群肺病患者。结果显示无手术死亡,术后痰菌阴转率93.9%,复发率6.5%,5年无复发概率80.2%,提示手术联合化疗安全有效。

要点

  • 肺切除联合围手术期多药化疗治疗脓肿分枝杆菌复合群肺病安全可行。
  • 术后痰菌阴转率达93.9%,复发率低(6.5%)。
  • 5年无复发概率为80.2%,长期疗效较好。

核心结论

  • 联合术前和术后多药化疗,肺切除术可安全施行并为脓肿分枝杆菌复合群肺病患者带来良好结局。

研究设计与样本

  • 回顾性综述,纳入2008年1月至2019年12月日本单中心33例因脓肿分枝杆菌复合群肺病接受肺切除术的患者。

主要发现

  • 中位年龄54.0岁(IQR 49.0-66.0),女性27例(81.8%)。
  • 结节支气管扩张型最常见(24例,72.7%),病变局限18例(54.5%),广泛15例(45.5%)。
  • 共行34次解剖性肺切除:肺叶切除22例,肺段切除5例,联合切除4例,双肺叶切除2例,全肺切除1例。
  • 无手术死亡,术后并发症4例(13.3%)。
  • 术后痰菌阴转31例(93.9%);术前阴转的23例均保持阴性,术前阳性的10例中8例(80.0%)术后转阴;复发2例(6.5%)。

关键数值与推荐

  • 术前多药化疗(口服和肠外抗生素)中位持续时间10.0个月(IQR 3.0-18.0)。
  • 术后多药化疗中位持续时间18.0个月(IQR 12.0-31.0)。

临床怎么用

  • 对于脓肿分枝杆菌复合群肺病,在规范多药化疗基础上联合肺切除术可提高痰菌阴转率并降低复发。
  • 术前应充分评估病变范围,制定个体化手术方案,术后需长期多药化疗并密切随访。

局限性

  • 单中心回顾性研究,样本量较小(33例),可能存在选择偏倚。
  • 缺乏非手术对照组,无法直接比较手术与单纯药物治疗的疗效差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycobacterium abscessus complex pulmonary disease is notoriously difficult to treat by medication alone. We report our experience with resectional surgery combined with preoperative and postoperative multidrug chemotherapy for the treatment of patients with M. abscessus complex pulmonary disease. METHODS: This is a retrospective review of 33 patients undergoing lung resection for M. abscessus complex pulmonary disease at a single center in Japan between January 2008 and December 2019. RESULTS: The median age of patients was 54.0 (interquartile range [IQR], 49.0-66.0) years; 27 (81.8%) were female. Nodular-bronchiectatic was the most common disease type (n = 24, 72.7%). Disease was limited in 18 (54.5%) patients and extensive in 15 (45.5%). The median duration of preoperative multidrug chemotherapy employing oral and parenteral antibiotics was 10.0 (IQR, 3.0-18.0) months. A total of 34 anatomical lung resections were performed as follows: 22 lobectomies, 5 segmentectomies, 4 combined resections, 2 bilobectomies, and 1 pneumonectomy. No operative mortalities and 4 (13.3%) morbidities occurred. The median duration of multidrug chemotherapy after the surgery was 18.0 (IQR, 12.0-31.0) months. Postoperative sputum-negative status was achieved in 31 (93.9%) patients; all 23 patients obtaining preoperative negative conversion remained negative, and 8 (80.0%) of 10 patients with preoperative positive sputum became negative postoperatively. Recurrence was observed in 2 (6.5%) patients. The recurrence-free probabilities were 96.3%, 96.3%, and 80.2% at 1 year, 3 years, and 5 years, respectively. CONCLUSIONS: Combined with preoperative and postoperative multidrug chemotherapy, resectional surgery can be performed safely and achieve favorable outcomes for patients with M. abscessus complex pulmonary disease.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Togo T, Atsumi J, Hiramatsu M, et al. Outcomes of Surgical Treatment for Mycobacterium abscessus Complex Pulmonary Disease. Ann Thorac Surg. 2021. PMID: 33839127. doi:10.1016/j.athoracsur.2021.03.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。